Optimal amount of monocyte chemoattractant protein-1 enhances antitumor effects of suicide gene therapy against hepatocellular carcinoma by M1 macrophage activation

Cancer Science

Volumn 99, Issue 10, 2008, Pages 2075-2082

  Tsuchiyama, Tomoya ^a   Nakamoto, Yasunari ^a   Sakai, Yoshio ^a   Mukaida, Naofumi ^a   Kaneko, Shuichi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 18; MONOCYTE CHEMOTACTIC PROTEIN 1; THYMIDINE KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BAGG ALBINO MOUSE; CANCER INHIBITION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG POTENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MACROPHAGE ACTIVATION; MALE; MONOTHERAPY; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUICIDE GENE THERAPY; TH1 CELL; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CHEMOKINE CCL2; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE THERAPY; GENES, TRANSGENIC, SUICIDE; GENETIC VECTORS; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS, EXPERIMENTAL; MACROPHAGE ACTIVATION; MACROPHAGES, PERITONEAL; MALE; MICE; MICE, NUDE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 54949131724     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.00951.x     Document Type: Article

References (29)

1. Okada H, Miyamura K, Itoh T et al. Gene therapy against an experimental glioma using adeno-associated virus vectors. Gene Ther 1996; 3: 957-64.
2. Coll JL, Mesnil M, Lefebvre MF, Lancon A, Favrot MC. Long-term survival of immunocompetent rats with intraperitoneal colon carcinoma tumors using herpes simplex thymidine kinase/ganciclovir and IL-2 treatments. Gene Ther 1997; 4: 1160-6.
3. Tsuchiyama T, Kaneko S, Nakamoto Y et al. Enhanced antitumor effects of a bicistronic adenovirus vector expressing both herpes simplex virus thymidine kinase and monocyte chemoattractant protein-1 against hepatocellular carcinoma. Cancer Gene Ther 2003; 10: 260-9.
4. Kagaya T, Nakamoto Y, Sakai Y et al. Monocyte chemoattractant protein-1 gene delivery enhances antitumor effects of herpes simplex virus thymidine kinase/ganciclovir system in a model of colon cancer. Cancer Gene Ther 2006; 13: 357-66.
5. Matsushima K, Larsen CG, DuBois GC, Oppenheim JJ. Purification and characterization of a novel monocyte chemotactic and activating factor produced by a human myelomonocytic cell line. J Exp Med 1989; 169: 1485-90.
6. Rollins BJ, Sunday ME. Suppression of tumor formation in vivo by expression of the JE gene in malignant cells. Mol Cell Biol 1991; 11: 3125-31.
7. Nokihara H, Yanagawa H, Nishioka Y et al. Natural killer cell-dependent suppression of systemic spread of human lung adenocarcinoma cells by monocyte chemoattractant protein-1 gene transfection in severe combined immunodeficient mice. Cancer Res 2000; 60: 7002-7.
8. Ueno T, Toi M, Saji H et al. Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res 2000; 6: 3282-9.
9. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: Tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002; 23: 549-55.
10. Kijima T, Osaki T, Nishino K et al. Application of the Cre recombinase/ loxP system further enhances antitumor effects in cell type-specific gene therapy against carcinoembryonic antigen-producing cancer. Cancer Res 1999; 59: 4906-11.
11. Freund CT, Sutton MA, Dang T, Contant CF, Rowley D, Lerner SP. Adenovirus-mediated combination suicide and cytokine gene therapy for bladder cancer. Anticancer Res 2000; 20: 1359-65.
12. Sakai Y, Kaneko S, Sato Y et al. Gene therapy for hepatocellular carcinoma using two recombinant adenovirus vectors with alpha-fetoprotein promoter and Cre/lox P system. J Virol Meth 2001; 92: 5-17.
13. Sato Y, Tanaka K, Lee G et al. Enhanced and specific gene expression via tissue-specific production of Cre recombinase using adenovirus vector. Biochem Biophys Res Commun 1998; 244: 455-62.
14. Sakai Y, Kaneko S, Nakamoto Y, Kagaya T, Mukaida N, Kobayashi K. Enhanced anti-tumor effects of herpes simplex virus thymidine kinase/ ganciclovir system by codelivering monocyte chemoattractant protein-1 in hepatocellular carcinoma. Cancer Gene Ther 2001; 8: 695-704.
15. Kawaguchi T, Suematsu M, Koizumi HM et al. Activation of macrophage function by intraperitoneal administration of the streptococcal antitumor agent OK-432. Immunopharmacology 1983; 6: 177-89.
16. Lamont AG, Adorini L. IL-12: A key cytokine in immune regulation. Immunol Today 1996; 17: 214-7.
17. Okamura H, Kashiwamura S, Tsutsui H, Yoshimoto T, Nakanishi K. Regulation of interferon-gamma production by IL-12 and IL-18. Curr Opin Immunol 1998; 10: 259-64.
18. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001; 19: 683-765.
19. Matsukawa A, Lukacs NW, Standiford TJ, Chensue SW, Kunkel SL. Adenoviral-mediated overexpression of monocyte chemoattractant protein-1 differentially alters the development of Th1 and Th2 type responses in vivo. J Immunol 2000; 164: 1699-704.
20. Tsuchiyama T, Nakamoto Y, Sakai Y et al. Prolonged, NK cell-mediated antitumor effects of suicide gene therapy combined with monocyte chemoattractant protein-1 against hepatocellular carcinoma. J Immunol 2007; 178: 574-83.
21. Okita K. Management of hepatocellular carcinoma in Japan. J Gastroenterol 2006; 41: 100-6.
22. Mizuguchi H, Xu Z, Ishii-Watabe A, Uchida E, Hayakawa T. IRES-dependent second gene expression is significantly lower than cap-dependent first gene expression in a bicistronic vector. Mol Ther 2000; 1: 376-82.
23. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004; 25: 677-86.
24. Biswas SK, Gangi L, Paul S et al. A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). Blood 2006; 107: 2112-22.
25. Mantovani A, Bottazzi B, Colotta F, Sozzani S, Ruco L. The origin and function of tumor-associated macrophages. Immunol Today 1992; 13: 265-70.
26. Nesbit M, Schaider H, Miller TH, Herlyn M. Low-level monocyte chemoattractant protein-1 stimulation of monocytes leads to tumor formation in nontumorigenic melanoma cells. J Immunol 2001; 166: 6483-90.
27. Barba D, Hardin J, Sadelain M, Gage FH. Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc Natl Acad Sci USA 1994; 91: 4348-52.
28. Vile RG, Castleden S, Marshall J, Camplejohn R, Upton C, Chong H. Generation of an anti-tumour immune response in a non-immunogenic tumour: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoural cytokine expression. Int J Cancer 1997; 71: 267-74.
29. Ramesh R, Marrogi AJ, Munshi A, Abboud CN, Freeman SM. In vivo analysis of the 'bystander effect': A cytokine cascade. Exp Hematol 1996; 24: 829-38.